Immunome (NASDAQ:IMNM) Insider Sells $2,273,555.44 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Kinney Horn sold 90,616 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total value of $2,273,555.44. Following the transaction, the insider directly owned 50,366 shares in the company, valued at approximately $1,263,682.94. The trade was a 64.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kinney Horn also recently made the following trade(s):

• On Tuesday, July 7th, Kinney Horn sold 1,092 shares of Immunome stock. The stock was sold at an average price of $25.00, for a total value of $27,300.00.

Immunome Stock Performance

IMNM stock traded up $0.30 on Thursday, hitting $25.82. 832,002 shares of the company’s stock were exchanged, compared to its average volume of 1,389,713. The firm has a 50 day moving average price of $21.36 and a two-hundred day moving average price of $22.12. Immunome, Inc. has a 12-month low of $8.66 and a 12-month high of $27.65. The stock has a market cap of $2.92 billion, a P/E ratio of -10.85 and a beta of 2.08.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Sell-side analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on IMNM. Truist Financial boosted their target price on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Barclays assumed coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Leerink Partners dropped their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.17.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA lifted its position in Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the period. State Street Corp boosted its holdings in Immunome by 37.9% in the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after purchasing an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.